Free Trial

FY2025 Earnings Estimate for MediciNova Issued By B. Riley

MediciNova logo with Medical background

MediciNova, Inc. (NASDAQ:MNOV - Free Report) - Equities research analysts at B. Riley issued their FY2025 earnings estimates for MediciNova in a research note issued on Monday, June 16th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will earn ($0.30) per share for the year. B. Riley currently has a "Strong-Buy" rating and a $5.00 target price on the stock. The consensus estimate for MediciNova's current full-year earnings is ($0.24) per share. B. Riley also issued estimates for MediciNova's FY2026 earnings at ($0.33) EPS.

MediciNova (NASDAQ:MNOV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.08.

A number of other research firms have also commented on MNOV. Wall Street Zen began coverage on shares of MediciNova in a research report on Sunday, May 18th. They set a "hold" rating on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price target on shares of MediciNova in a research report on Wednesday, April 9th.

Check Out Our Latest Stock Analysis on MediciNova

MediciNova Stock Up 1.6%

Shares of MNOV traded up $0.02 during trading hours on Wednesday, hitting $1.29. The company had a trading volume of 11,758 shares, compared to its average volume of 36,502. The firm has a market cap of $63.27 million, a price-to-earnings ratio of -5.61 and a beta of 0.42. The business has a fifty day moving average of $1.42 and a 200-day moving average of $1.67. MediciNova has a 12 month low of $1.12 and a 12 month high of $2.55.

Hedge Funds Weigh In On MediciNova

A number of hedge funds have recently bought and sold shares of MNOV. Y Intercept Hong Kong Ltd acquired a new stake in MediciNova during the fourth quarter worth about $78,000. Bank of America Corp DE grew its stake in MediciNova by 111.3% during the fourth quarter. Bank of America Corp DE now owns 161,312 shares of the biopharmaceutical company's stock worth $339,000 after buying an additional 84,963 shares in the last quarter. Jane Street Group LLC grew its stake in MediciNova by 64.5% during the fourth quarter. Jane Street Group LLC now owns 23,259 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 9,121 shares in the last quarter. Barclays PLC grew its stake in MediciNova by 15.5% during the fourth quarter. Barclays PLC now owns 95,600 shares of the biopharmaceutical company's stock worth $201,000 after buying an additional 12,800 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in MediciNova by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 514,914 shares of the biopharmaceutical company's stock worth $1,082,000 after buying an additional 8,948 shares in the last quarter. 9.90% of the stock is owned by institutional investors.

About MediciNova

(Get Free Report)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

Further Reading

Should You Invest $1,000 in MediciNova Right Now?

Before you consider MediciNova, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.

While MediciNova currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines